Loading...

TKD

TK

TAKEDA PHARMACEUTICAL CO LTD

(TAK)

2024 6-K

Psoriasis Treatment Update

30 Mar '26

Board Changes Announced

26 Mar '26

Transformation Plans

25 Mar '26

Drug Approval Update

2 Mar '26

FDA Accepts NDA

10 Feb '26

Earnings Report Update

29 Jan '26

Psoriasis Treatment Data

18 Dec '25

Rusfertide Updates

8 Dec '25

Form 6-K Filing

28 Nov '25

Semi-annual Report

30 Oct '25

Earnings Report

30 Oct '25

Financial Forecast Update

30 Oct '25

Cell Therapy Update

1 Oct '25

Reserve Changes

25 Sep '25

Orexin Data Presentation

8 Sep '25

Oveporexton Disclosure

31 Jul '25

Earnings Report Summary

30 Jul '25

Positive Clinical Results

14 Jul '25

Corporate Governance Report

9 Jul '25

Treasury Shares Disposal

8 Jul '25

Debt Instruments Update

2 Jul '25

Shareholder Meeting Results

1 Jul '25

Annual Report Filing

30 Jun '25

Director Assignments Update

25 Jun '25

Annual Meeting Results

25 Jun '25

Share Repurchase Update

12 Jun '25

Treasury Share Disposal

10 Jun '25

Board Meeting Statement

6 Jun '25

Shelf Registration Update

2 Jun '25

Rusfertide Study Results

2 Jun '25

Executive Compensation Over...

28 May '25

Shareholder Update

28 May '25

6K Filing Summary

28 May '25

Shareholder Meeting Notice

28 May '25

Share Repurchase Update

14 May '25

Stock Compensation Plan

8 May '25

Earnings Report Summary

8 May '25

Share Buyback Completed

22 Apr '25

Share Repurchase Update

14 Apr '25

Share Buyback Update

1 Apr '25

Board Candidates Update

26 Mar '25

Share Repurchase Report

13 Mar '25

Positive Study Results

3 Mar '25

Share Buyback Update

3 Mar '25

Share Repurchase Update

13 Feb '25

CEO Succession Announcement

30 Jan '25

Soticlestat Discontinued

30 Jan '25

Share Buyback Announcement

30 Jan '25

Financial Forecast Update

30 Jan '25

Earnings Report Summary

30 Jan '25

Subsidiary Merger Update

18 Dec '24

Pipeline Update

13 Dec '24

Form 6-K Filing

2 Dec '24

Takeda Filing Update

31 Oct '24

Financial Highlights

31 Oct '24

Revised Financial Outlook

31 Oct '24

Subsidiary Merger

26 Sep '24

Earnings Report Highlights

31 Jul '24

Corporate Governance Report

10 Jul '24

New Share Issuance

9 Jul '24

Debt Issuance Report

5 Jul '24

Shareholder Voting Results

2 Jul '24

Annual Report Submission

1 Jul '24

Director Assignments

26 Jun '24

Shareholder Meeting

26 Jun '24

Takeda Soticlestat Update

17 Jun '24

Share Issuance Plan

11 Jun '24

Meeting Correction

10 Jun '24

Board Response Insights

7 Jun '24

Hybrid Bonds Pricing

7 Jun '24

Positive Trial Results

3 Jun '24

Shelf Registration Update

3 Jun '24

Executive Compensation Over...

29 May '24

Filing Overview

29 May '24

Filing Notification

29 May '24

Shareholders Meeting Notice

29 May '24

Financial Correction

21 May '24

Stock Compensation Plan

9 May '24

Board Member Passing

9 May '24

Growth Program Announcement

9 May '24

FY2023 Results Discrepancy

9 May '24

Financial Results Summary

9 May '24

FDA Approval

19 Apr '24

Bond Issuance Announcement

15 Apr '24

Board Candidates Announced

27 Mar '24

Phase 3 Trials

9 Feb '24

Quarterly Earnings Update

2 Feb '24

CFO Succession

1 Feb '24

Financial Results Summary

1 Feb '24

Company Split Announced

16 Jan '24

External Links:

SEC

Takeda Pharmaceutical Co. announced plans to quickly start global Phase 3 trials of TAK-861, an oral treatment for narcolepsy type 1, following positive Phase 2b trial results reported on February 8, 2024.

AI Assistant

TAKEDA PHARMACEUTICAL CO LTD

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.